

No.DCG(I)/MISC/2013
Directorate General of Health Services
O/o Drugs Controller General India
FDA Bhawan, Kotla Road, New Delhi

Dated: 26th June, 2013.

To

All States/UTs Drugs Controller

**Subject: Re-labeling/Re-printing of revised prices as per NPPA's –
Notification regarding.**


Sir,

In pursuance to the National Pharmaceuticals Pricing Authority's (NPPA) recent Order/Notifications No.1542 (E) to 1692 (E) dated 14th June, 2013, and subsequent notifications in this regard which will follow for revising the ceiling price of the scheduled formulations, the NPPA is fixing the ceiling prices of scheduled formulations produced or available in the market. Accordingly, the manufacturers are required to ensure within a period of forty-five days of the date of the notification that the maximum retail price of such scheduled formulation does not exceed the ceiling price (plus local taxes as applicable).

Consequent to the fixing of ceiling prices of the scheduled formulations by NPPA as per the above, the manufacturers may be required to re-print/re-label the revised prices of scheduled formulations produced or available in the market.

Accordingly, the office of DCG (I) does not have any objection for re-labeling/stickering of the drugs concerned under Rule 104A of Drugs & Cosmetics Rules for this purpose. Since the activity involved is large, it is necessary to take the practical approach to expedite re-printing of price, so that benefits of price reduction can be passed on to the consumers.

Yours faithfully,


(Dr. G.N. Singh)
Drugs Controller General (I)

Copy to:

1. Chairman, National Pharmaceuticals Pricing Authority's, New Delhi.
2. Secretary, Department of Pharmaceuticals, Shastri Bhawan, New Delhi.
3. Additional Secretary & DG (CGHS), Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi.

C.C. to:

IDMA/OPPI/IPA/BDMA/Others